Overview

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Status:
Recruiting
Trial end date:
2026-06-02
Target enrollment:
Participant gender:
Summary
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Luspatercept